HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $237,204,084 | +1.1% | 6,209,531 | -4.5% | 0.01% | +8.3% |
| Q2 2023 | $234,610,137 | +3.2% | 6,504,301 | +9.2% | 0.01% | -7.7% |
| Q1 2023 | $227,412,857 | -65.0% | 5,954,775 | -47.9% | 0.01% | -31.6% |
| Q4 2022 | $650,254,680 | +166.4% | 11,428,026 | +85.1% | 0.02% | +26.7% |
| Q3 2022 | $244,095,000 | -6.2% | 6,173,378 | +4.4% | 0.02% | -6.2% |
| Q2 2022 | $260,293,000 | +5.9% | 5,915,747 | -4.1% | 0.02% | +33.3% |
| Q1 2022 | $245,905,000 | +4.3% | 6,166,127 | +5.2% | 0.01% | +9.1% |
| Q4 2021 | $235,664,000 | +3.9% | 5,860,832 | +5.1% | 0.01% | -8.3% |
| Q3 2021 | $226,804,000 | -3.2% | 5,575,317 | +8.0% | 0.01% | 0.0% |
| Q2 2021 | $234,397,000 | +11.7% | 5,161,793 | +2.6% | 0.01% | 0.0% |
| Q1 2021 | $209,835,000 | -11.1% | 5,033,216 | -8.9% | 0.01% | -14.3% |
| Q4 2020 | $236,007,000 | +97.1% | 5,525,812 | +21.3% | 0.01% | +75.0% |
| Q3 2020 | $119,716,000 | -14.7% | 4,555,413 | -12.9% | 0.01% | -20.0% |
| Q2 2020 | $140,297,000 | +78.7% | 5,233,006 | +19.9% | 0.01% | +42.9% |
| Q1 2020 | $78,512,000 | -1.4% | 4,364,183 | -2.8% | 0.01% | +40.0% |
| Q4 2019 | $79,623,000 | +13.8% | 4,490,873 | -0.4% | 0.01% | 0.0% |
| Q3 2019 | $69,964,000 | -8.0% | 4,510,918 | +1.9% | 0.01% | -16.7% |
| Q2 2019 | $76,081,000 | +19.5% | 4,428,475 | +12.0% | 0.01% | +20.0% |
| Q1 2019 | $63,658,000 | +5.9% | 3,953,883 | -3.7% | 0.01% | 0.0% |
| Q4 2018 | $60,093,000 | -23.9% | 4,107,501 | -5.4% | 0.01% | -16.7% |
| Q3 2018 | $78,917,000 | +2.2% | 4,343,168 | -5.1% | 0.01% | 0.0% |
| Q2 2018 | $77,191,000 | -21.2% | 4,575,701 | -8.5% | 0.01% | -25.0% |
| Q1 2018 | $97,923,000 | +14.1% | 4,998,718 | +18.0% | 0.01% | +14.3% |
| Q4 2017 | $85,821,000 | +34.3% | 4,235,972 | +15.1% | 0.01% | +16.7% |
| Q3 2017 | $63,900,000 | +35.7% | 3,678,698 | +0.1% | 0.01% | +50.0% |
| Q2 2017 | $47,106,000 | +0.6% | 3,674,238 | +1.6% | 0.00% | 0.0% |
| Q1 2017 | $46,842,000 | +24.1% | 3,614,672 | -5.4% | 0.00% | 0.0% |
| Q4 2016 | $37,742,000 | -4.2% | 3,819,690 | +17.1% | 0.00% | 0.0% |
| Q3 2016 | $39,398,000 | +27.6% | 3,261,211 | -8.9% | 0.00% | +33.3% |
| Q2 2016 | $30,880,000 | -6.1% | 3,578,450 | +3.1% | 0.00% | -25.0% |
| Q1 2016 | $32,884,000 | -36.7% | 3,472,472 | +15.9% | 0.00% | -33.3% |
| Q4 2015 | $51,931,000 | +24.6% | 2,996,665 | -3.4% | 0.01% | +20.0% |
| Q3 2015 | $41,679,000 | -38.2% | 3,103,381 | +3.9% | 0.01% | -28.6% |
| Q2 2015 | $67,414,000 | +53.4% | 2,985,625 | -3.0% | 0.01% | +40.0% |
| Q1 2015 | $43,937,000 | +22.2% | 3,076,968 | -17.4% | 0.01% | +25.0% |
| Q4 2014 | $35,950,000 | +20.8% | 3,725,138 | +13.9% | 0.00% | +33.3% |
| Q3 2014 | $29,763,000 | -0.2% | 3,270,710 | +8.4% | 0.00% | 0.0% |
| Q2 2014 | $29,820,000 | -20.9% | 3,018,348 | +1.6% | 0.00% | -25.0% |
| Q1 2014 | $37,720,000 | -34.9% | 2,969,709 | -44.4% | 0.00% | 0.0% |
| Q4 2013 | $57,905,000 | +38.0% | 5,345,547 | +40.6% | 0.00% | -20.0% |
| Q3 2013 | $41,968,000 | +41.5% | 3,801,420 | +1.8% | 0.01% | +25.0% |
| Q2 2013 | $29,656,000 | – | 3,734,670 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |